生物
糖酵解
癌症研究
肺癌
转移
细胞生长
癌症
细胞
细胞培养
肺
厌氧糖酵解
肿瘤进展
癌细胞
腺癌
新陈代谢
基因表达调控
作者
Fulei Zhao,Fanlian Zeng,Pei Zhou,Huaping Zheng,Yue Hu,Jie Tang,Yawen Hu,Guolin Li,Yuting Feng,Xiaoyan Wang,Jiadong Yu,Y P. Li,Chengcheng Yue,Xiao Liu,Tingting Zhang,Nongyu Huang,Xiaochi Sun,Xinmeng Wang,Shishi Huang,Mingxiang He
标识
DOI:10.1186/s12943-026-02684-9
摘要
Metabolic reprogramming, particularly aberrant glycolysis, is a hallmark of NSCLC progression; however, the regulatory mechanisms remain incompletely understood. Here, we identify SerpinB7, an endogenous serine protease inhibitor, as a novel oncogenic regulator of glycolytic reprogramming in NSCLC. SerpinB7 is significantly overexpressed in NSCLC tissues and correlates with poor prognosis. Mechanistically, SerpinB7 functions in a non-canonical, protease-independent manner by directly binding to Annexin A2 (ANXA2), protecting it from NEDD4L-mediated ubiquitination and degradation, thereby stabilizing ANXA2 protein levels.As an RNA-binding protein, ANXA2 interacts with c-Myc via its C-terminal domain, enhancing c-Myc driven transcription of glycolytic genes. This establishes a previously unrecognized SerpinB7-ANXA2-c-Myc regulatory axis that promotes glycolytic activation and malignant transformation in NSCLC cells. Importantly, immunohistochemical analysis of clinical specimens confirms the co-overexpression of SerpinB7 and ANXA2 in tumors, underscoring the clinical relevance of this pathway. Targeting SerpinB7 using siRNAs encapsulated in ferritin protein shells effectively suppresses NSCLC tumor growth and metastasis. These findings reveal SerpinB7 as a tumor-specific modulator of glycolysis and a potential metabolic target in NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI